Research Focus

Molecular Pharmacology Program; Research Technician, Sr

Recent additions – View all

1. RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

   Meeting Abstract

   Yuan, X.; Zhang, X.; Du, R.; Cheung, S. H.; Wei, M.; Zhou, C.; Wang, L.; Shearer, T.; Edris, B.; Smith, M.; more...
   Cancer Research (2020)

   Fulltext@MSK | Save
2. Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer

   Journal Article

   Yaeger, R.; Kotani, D.; Mondaca, S.; Parikh, A. R.; Bando, H.; Van Seventer, E. E.; Taniguchi, H.; Zhao, H.; Thant, C. N.; de Stanchina, E.; more...
   Clinical Cancer Research (2019)

   Fulltext@MSK | Save